Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog

Blood

Volumn 106, Issue 3, 2005, Pages 996-1002

  Boggon, Titus J ^b   Li, Yiqun ^b   Manley, Paul W ^b   Eck, Michael J ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; AFN 941; ARGININE; CYTOKINE RECEPTOR; IMATINIB; IMMUNOSUPPRESSIVE AGENT; JANUS KINASE; JANUS KINASE 3; JANUS KINASE 3 INHIBITOR; PHOSPHATE; PROTEIN TYROSINE KINASE; STAT PROTEIN; STAUROSPORINE DERIVATIVE; TYROSINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; COMBINED IMMUNODEFICIENCY; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG SELECTIVITY; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME INHIBITION; GENE MUTATION; HUMAN; IMMUNOREGULATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS;

EID: 23044495944     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2005-02-0707     Document Type: Article

References (39)

1. Rane SG, Reddy EP. Janus kinases: components of multiple signaling pathways. Oncogene. 2000; 19:5662-5679.
2. Imada K, Leonard WJ. The Jak-STAT pathway. Mol Immunol. 2000;37:1-11.
3. Saharinen P, Takaluoma K, Silvennoinen O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol Cell Biol. 2000;20: 3387-3395.
4. O'Shea JJ, Husa M, Li D, et al. Jak3 and the pathogenesis of severe combined immunodeficiency. Mol Immunol. 2004;41:727-737.
5. Buckley RH, Schiff RI, Schiff SE, et al. Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. J Pediatr. 1997;130:378-387.
6. Mella P, Schumacher RF, Cranston T, de Saint Basile G, Savoldi G, Notarangelo LD. Eleven novel JAK3 mutations in patients with severe combined immunodeficiency-including the first patients with mutations in the kinase domain. Hum Mutat. 2001;18:355-356.
7. Notarangelo LD, Mella P, Jones A, et al. Mutations in severe combined immune deficiency (SCID) due to JAK3 deficiency. Hum Mutat. 2001; 18:255-263.
8. Roberts JL, Lengi A, Brown SM, et al. Janus kinase 3 (JAK3) deficiency: clinical, immunologic, and molecular analyses of 10 patients and outcomes of stem cell transplantation. Blood. 2004; 103:2009-2018.
9. O'Shea JJ, Pesu M, Borie DC, Changelian PS. A new modality for immunosuppression: targeting the JAK/STAT pathway. Nat Rev Drug Discov. 2004;3:555-564.
10. Papageorgiou AC, Wikman LE. Is JAK3 a new drug target for immunomodulation-based therapies? Trends Pharmacol Sci. 2004;25:558-562.
11. Verma A, Kambhampati S, Parmar S, Platanias LC. Jak family of kinases in cancer. Cancer Metastasis Rev. 2003;22:423-434.
12. Lacronique V, Boureux A, Valle VD, et al. ATEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science. 1997;278:1309-1312.
13. Danial NN, Pernis A, Rothman PB. Jak-STAT signaling induced by the v-abl oncogene. Science. 1995;269:1875-1877.
14. Chai SK, Nichols GL, Rothman P. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol. 1997; 159:4720-4728.
15. Shuai K, Halpern J, ten Hoeve J, Rao X, Sawyers CL. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene. 1996;13:247-254.
16. Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science. 2003;302:875-878.
17. Kawamura M, McVicar DW, Johnston JA, et al. Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes. Proc Natl Acad Sci U S A. 1994;91:6374-6378.
18. Takahashi T, Shirasawa T. Molecular cloning of rat JAK3, a novel member of the JAK family of protein tyrosine kinases. FEBS Lett. 1994;342: 124-128.
19. Pane SG, Reddy EP. JAK3: a novel JAK kinase associated with terminal differentiation of hemaiopoietic cells. Oncogene. 1994;9:2415-2423.
20. Otwinowski Z. Oscillation data reduction program. In: Sawyer L, Isaacs N, Burley S, eds. Proceedings of the CCP4 Study Weekend. Daresbury, United Kingdom: SERC Daresbury Laboratory; 1993:56-62.
21. Brunger AT, Adams PD, Clore GM, et al. Crystallography & NMR system: a new software suite for macro-molecular structure determination. Acta Crystallogr D Biol Crystallogr. 1998;54:905-921.
22. Laskowski RA, Rullmannn JA, MacArthur MW, Kaptein R, Thornton JM. AQUA and PRO-CHECK-NMR: programs for checking the quality of protein structures solved by NMR. J Biomol NMR. 1996;8:477-486.
23. Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. Acta Cryst D Biol Crystallogr. 1994;50(pt 5):760-773.
24. Read RJ. Pushing the boundaries of molecular replacement with maximum likelihood. Acta Crystallogr D Biol Crystallogr. 2001;57:1373-1382.
25. Lamzin VS, Wilson KS. Automated refinement for protein crystallography. Methods Enzymol. 1997; 277:269-305.
26. Jones TA, Zhou JY, Cowan SW, Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A. 1991;47:110-119.
27. Schuttelkopf AW, van Aalten DM. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr. 2004;60:1355-1363.
28. Huse M, Kuriyan J. The conformational plasticity of protein kinases. Cell. 2002;109:275-282.
29. Nagar B, Bornmann WG, Pellicena P, et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 2002;62:4236-4243.
30. Yamaguchi H, Hendrickson WA. Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature. 1996;384: 484-489.
31. Hubbard SR. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J. 1997;16:5572-5581.
32. Favelyukis S, Till JH, Hubbard SR, Miller WT. Structure and autoregulation of the insulin-like growth factor 1 receptor kinase. Nat Struct Biol. 2001;8:1058-1063.
33. McTigue MA, Wickersham JA, Pinko C, et al. Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis. Structure Fold Des. 1999;7:319-330.
34. Knighton DR, Zheng JH, Ten EL, et al. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science. 1991;253:407-414.
35. Evans SV. SETOR: hardware lighted three-dimensional solid model representations of macromolecules. J Mol Graphics. 1993;11:134-138.
36. Zhou YJ, Hanson EP, Chen YQ, et al. Distinct tyrosine phosphorylation sites in JAK3 kinase domain positively and negatively regulate its enzymatic activity. Proc Natl Acad Sci U S A. 1997;94: 13850-13855.
37. Jacob KK, Whittaker J, Stanley FM. Insulin receptor tyrosine kinase activity and phosphorylation of tyrosines 1162 and 1163 are required for insulin-increased prolactin gene expression. Mol Cell Endocrinol. 2002;186:7-16.
38. Zhu X, Kim JL, Newcomb JR, et al. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. Structure Fold Des. 1999;7: 651-661.
39. Jin L, Pluskey S, Petrella EC, et al. The three-dimensional structure of the ZAP-70 kinase domain in complex with staurosporine: implications for the design of selective inhibitors. J Biol Chem. 2004;279:42818-42825.